Discover and read the best of Twitter Threads about #granules
Most recents (18)
1. Generated operational cash of 218 cr vs 181 cr in Q1 22
2. Free cash flow of 124 cr vs 98 cr in Q1 23
3. Completed the buy back with total cash outflow of 310 cr including taxes and other expenses
2. Free cash flow of 124 cr vs 98 cr in Q1 23
3. Completed the buy back with total cash outflow of 310 cr including taxes and other expenses
4. Raw material costs coming down but coal prices increased in current qtr
5. Supply of PAP and DCDA is stable and improving
6. Work on the DCDA project is going on smoothly and expecting results in less than 2 years.
5. Supply of PAP and DCDA is stable and improving
6. Work on the DCDA project is going on smoothly and expecting results in less than 2 years.
1. The Double Bottom:
A trend reversal pattern.
Two lows of similar levels are formed.
ENTRY:
BO of the Neckline shows trend reversal by forming a Higher swing high which is also the entry point.
SL: LOD or swing low at a lower TF
TARGET:
Height of the NL to B1
Eg: #GRANULES
A trend reversal pattern.
Two lows of similar levels are formed.
ENTRY:
BO of the Neckline shows trend reversal by forming a Higher swing high which is also the entry point.
SL: LOD or swing low at a lower TF
TARGET:
Height of the NL to B1
Eg: #GRANULES
2. The Volatility contraction pattern, VCP by Mark Minervini
After a prior uptrend, a stock digests its gains, and profit taking happens. It then bases and gets ready for the next uptrend. VCP is a characteristic of a constructive base. It has the following characteristics:
1/n
After a prior uptrend, a stock digests its gains, and profit taking happens. It then bases and gets ready for the next uptrend. VCP is a characteristic of a constructive base. It has the following characteristics:
1/n
#Granules Q3 FY22 concall highlights 💊
Like & Retweet for better reach !
1. Revenue for the quarter stood at ₹996.8 Cr (18% growth YoY).
2. EBITDA for the quarter was at ₹173 Cr (17.9% decline YoY).
3. EBITDA margins were at 17.4% compared to 25.1% in Q3 FY21.
Like & Retweet for better reach !
1. Revenue for the quarter stood at ₹996.8 Cr (18% growth YoY).
2. EBITDA for the quarter was at ₹173 Cr (17.9% decline YoY).
3. EBITDA margins were at 17.4% compared to 25.1% in Q3 FY21.
4. They faced challenges during the quarter such as RM price increases, unstable supply from China and logistics issues. Their volumes were down compared to last year but they have been able to pass on a significant amount of price increases to their customers.
5. The overall gross margin recorded is lower due to change in segment mix in the total revenue. Share of Finished dosage has come down from 57% in Q2 to 46% in Q3 due to higher inventory build-up at USA and year end.
Insights on the Indian API, Formulation and CRAMS via a recent report from o3 Capital.
Tailwinds (China+1): 10% market share switch from China can double Indian API market.
Headwinds: Rising input costs in China due to power outage + freight hike. India has high dependency.
1/n
Tailwinds (China+1): 10% market share switch from China can double Indian API market.
Headwinds: Rising input costs in China due to power outage + freight hike. India has high dependency.
1/n
2/n
Indian API landscape
Scale, capacity, DMF filings, focus segments/ therapy areas and leading products.
#Divis #LaurusLabs #Granules #AartiDrugs #Solara
Indian API landscape
Scale, capacity, DMF filings, focus segments/ therapy areas and leading products.
#Divis #LaurusLabs #Granules #AartiDrugs #Solara
3/n
Growth strategies adopted by API companies
- Diversifying beyond API and CRAMS into Formulations, Biologics and Nutraceuticals.
- Laurus: Forward integrated into drug development via contracts from NATCO, Citron, Dr. Reddy + foray into new markets + new segments (Biologics)
Growth strategies adopted by API companies
- Diversifying beyond API and CRAMS into Formulations, Biologics and Nutraceuticals.
- Laurus: Forward integrated into drug development via contracts from NATCO, Citron, Dr. Reddy + foray into new markets + new segments (Biologics)
1 new chart everyday, it could be from any space ~ equities / commodities / crypto / forex / bonds , etc
Will try to do it daily 🙏💪
Here's the first one 👇
SBI vs BankNifty
Ratio chart has given monthly breakout implying SBI could outperform BN in coming months.
#PB365
Will try to do it daily 🙏💪
Here's the first one 👇
SBI vs BankNifty
Ratio chart has given monthly breakout implying SBI could outperform BN in coming months.
#PB365
@GranulesIndia
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations
#stocks
Q2fy21
Revenue up 22.7% to 858 crs
Formulations up 22.4% yoy 430 crs
API up 17% to 255
PFI up 32.6% to 173 crs
Vizag unit V commissioned for API ,oncology segment,
Company plans gradual shift from commoditized API to more complex drugs/ Formulations
#stocks
Company expects to commission MUPS block by Q3fy22
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier
#StockMarket #Nifty
- Revenue contribution of core mols dropped to 70 from 80-85% end of Fy20
- #granules has 32 ANDA approved ,expect to launch 6 of these in Fy21
- Revised PAT guidance to 30% post Fy21 from 25% earlier
#StockMarket #Nifty
Company plans 7-9 product filings/year, atleast 5 for the US market
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%
- Top 5 mols contributed 70%
- Capex guidance of 3.5 to 4 bn for fy21 & 3bn for Fy22
- Relaunch Metformin 750 mg in US over next year
- EU sales 23 % expected to reach 28% by Fy23, US sales to decline to 43%
@GranulesIndia earnings call transcript Q2fy21
No longer a 5 product company
22 launched products
PAT growth up 80% H1fy21 compared to H1fy20,due to fast approval of filed ANDAs,rapid scale up production
Ebidta,PAT > Rev growth- better product mix,sales,op efficiency
#Stocks
No longer a 5 product company
22 launched products
PAT growth up 80% H1fy21 compared to H1fy20,due to fast approval of filed ANDAs,rapid scale up production
Ebidta,PAT > Rev growth- better product mix,sales,op efficiency
#Stocks
32 approved ANDAs(6 yet to launch),13 waiting for approval
Expect 1 MUPS tech based ANDA in Q3 or Q4
Construction MUPS block on track,commercialize Q3fy22
High vol MUPS products & APIs next major driver
Q1fy21 recall of $2 mn tabs Metformin 750mg,this Q 1mn reversed into books
Expect 1 MUPS tech based ANDA in Q3 or Q4
Construction MUPS block on track,commercialize Q3fy22
High vol MUPS products & APIs next major driver
Q1fy21 recall of $2 mn tabs Metformin 750mg,this Q 1mn reversed into books
Stocks for 24/09/20 Intraday
Based on NR7:
#KOTAKBANK
#GLENMARK
#BIOCON
#TITAN
#ICICIPRULI
Based on NR4:
#BANDHANBNK
#HDFCBANK
#CIPLA
#GRANULES
#CADILAHC
Including NR4 too to increase my options for tomorrow
Based on NR7:
#KOTAKBANK
#GLENMARK
#BIOCON
#TITAN
#ICICIPRULI
Based on NR4:
#BANDHANBNK
#HDFCBANK
#CIPLA
#GRANULES
#CADILAHC
Including NR4 too to increase my options for tomorrow
Some of you asked what I meant by "Volatility Concept"
while selecting stocks
Basically, you don't want stocks which are not moving organically, doing pump/dump, staying flat, or forming too many gaps
These were NR7 stocks which I rejected because of above reasons:
while selecting stocks
Basically, you don't want stocks which are not moving organically, doing pump/dump, staying flat, or forming too many gaps
These were NR7 stocks which I rejected because of above reasons:
Results of the Day: 4/10 Stocks gave tradeable moves
A tricky, no easy setups day today
1/4 : #KOTAKBANK : PROFIT : +1.7R
As posted earlier:
It gave a loss of -1R, followed by another signal giving +2R
A tricky, no easy setups day today
1/4 : #KOTAKBANK : PROFIT : +1.7R
As posted earlier:
It gave a loss of -1R, followed by another signal giving +2R
#Thread of the top 3 stocks, sector wise
Industrial Conglomerate
#Siemens
#3M
#Godrej
Pharma
#Caplin
#Granules
#Natco
Electronics
#Dixon
#Amber
#Honeywell
(1/n)
.@dmuthuk .@Arunstockguru .@AnyBodyCanFly .@FI_InvestIndia .@Gautam__Baid .@contrarianEPS .@AswathDamodaran
Industrial Conglomerate
#Siemens
#3M
#Godrej
Pharma
#Caplin
#Granules
#Natco
Electronics
#Dixon
#Amber
#Honeywell
(1/n)
.@dmuthuk .@Arunstockguru .@AnyBodyCanFly .@FI_InvestIndia .@Gautam__Baid .@contrarianEPS .@AswathDamodaran
Health care
#Lalpath
#Kovai
#Narayanahru
Auto
#Eicher
#Maruti
#Hero / #Bajaj / #Escorts (#Tractor)
Auto parts
#Minda
#Motherson
#Subros / #Fiem
Communication & networking
#Sterlite
#Dlink
#Tejas
Chemicals (huge options)
#Kanchikarp
#Kilpest
#Bodal
(2/n)
.@ipo_mantra
#Lalpath
#Kovai
#Narayanahru
Auto
#Eicher
#Maruti
#Hero / #Bajaj / #Escorts (#Tractor)
Auto parts
#Minda
#Motherson
#Subros / #Fiem
Communication & networking
#Sterlite
#Dlink
#Tejas
Chemicals (huge options)
#Kanchikarp
#Kilpest
#Bodal
(2/n)
.@ipo_mantra
Biotech
#Syngene
#Eris
#Vivobio
Transport
#IRCTC
#Interglobe
Real estate
#Sunteck
#Nesco
#Oberoi
Logistics
#Allcargo
#TCI
#Mahindralog
Banking & related
#Creditaccess
#Bajajfinance
#Hdfcbank / #Kotak
Food
#ZYDUSWELLNESS
#Avanti
#Hindfoods
(3/n)
.@VJ_Rabindranath
#Syngene
#Eris
#Vivobio
Transport
#IRCTC
#Interglobe
Real estate
#Sunteck
#Nesco
#Oberoi
Logistics
#Allcargo
#TCI
#Mahindralog
Banking & related
#Creditaccess
#Bajajfinance
#Hdfcbank / #Kotak
Food
#ZYDUSWELLNESS
#Avanti
#Hindfoods
(3/n)
.@VJ_Rabindranath
Stocks for 17/09/20 Intraday
#BHARTIARTL
#BANDHANBNK
#JSWSTEEL
#BPCL
#TECHM
#UPL
#VOLTAS
#GRANULES
#PVR
#TATACONSUM
Based on NR7, Volume and Volatility concepts
#BHARTIARTL
#BANDHANBNK
#JSWSTEEL
#BPCL
#TECHM
#UPL
#VOLTAS
#GRANULES
#PVR
#TATACONSUM
Based on NR7, Volume and Volatility concepts
Results of the Day : 3/10 Stocks gave tradeable moves
Pretty average Day for me But Lots of Learning too
1/3 : #TECHM : LOSS : -0.3R
All details on Chart
LEARNING: I could have Maybe waited for pullback since Stock went up +2.65% with that huge candle
Good that I cut it Early
Pretty average Day for me But Lots of Learning too
1/3 : #TECHM : LOSS : -0.3R
All details on Chart
LEARNING: I could have Maybe waited for pullback since Stock went up +2.65% with that huge candle
Good that I cut it Early
2/3 : #TATACONSUM : PROFIT : +0.8R
Price rejected from previous highs and formed Bearish candles
Some have asked me about use of VWAP. I use it for trades like these. Here price bounced at VWAP which was not good for Short trade, hence closed
Price rejected from previous highs and formed Bearish candles
Some have asked me about use of VWAP. I use it for trades like these. Here price bounced at VWAP which was not good for Short trade, hence closed
Stocks for 16/09/20 Intraday
#SBIN
#ZEEL
#RELIANCE
#TATASTEEL
#JSWSTEEL
#INFRATEL
#GRANULES
#BAJFINANCE
#INDIGO
#ADANIPORTS
Based on NR7 Pattern Screener
chartink.com/screener/nr7-p…
& filtering on basis of Volume & Volatility
Do watch @ST_PYI Sir YT video on NR7 for details
#SBIN
#ZEEL
#RELIANCE
#TATASTEEL
#JSWSTEEL
#INFRATEL
#GRANULES
#BAJFINANCE
#INDIGO
#ADANIPORTS
Based on NR7 Pattern Screener
chartink.com/screener/nr7-p…
& filtering on basis of Volume & Volatility
Do watch @ST_PYI Sir YT video on NR7 for details
Results of the Day : 3/10 Stocks gave tradeable moves
1/3 : #BAJFINANCE : BREAKEVEN
Price broke through previous highs with all conditions met BUT stalled and didn't move and formed bearish candles
1/3 : #BAJFINANCE : BREAKEVEN
Price broke through previous highs with all conditions met BUT stalled and didn't move and formed bearish candles
2/3 : #TATASTEEL : PROFIT : +4R
As posted earlier today:
Price was rejected by previous highs and gave Short entry by forming bearish conditions.
Exited at +4R which is the maximum I target for Intraday trades
As posted earlier today:
Price was rejected by previous highs and gave Short entry by forming bearish conditions.
Exited at +4R which is the maximum I target for Intraday trades
Stocks for 15/09/20 Intraday
#INFRATEL
#JINDALSTEEL
#GRANULES
#ADANIPORTS
#CADILAHC
#LUPIN
#McDOWELL_N
#PEL
#RAMCOCEM
#JUBLFOOD
Based on NR7, Volume and Volatility concepts
#INFRATEL
#JINDALSTEEL
#GRANULES
#ADANIPORTS
#CADILAHC
#LUPIN
#McDOWELL_N
#PEL
#RAMCOCEM
#JUBLFOOD
Based on NR7, Volume and Volatility concepts
Results of the Day : 4/10 Stocks gave tradeable moves
1/4 : #LUPIN : PROFIT : +1.6R
Price was consolidating below resistance. It broke in the first 5 mins with Volume and strong Closing. I took the trade this early because of these reasons
1/4 : #LUPIN : PROFIT : +1.6R
Price was consolidating below resistance. It broke in the first 5 mins with Volume and strong Closing. I took the trade this early because of these reasons
2/4 : #PEL : BREAKEVEN
Price was below HTF resistance and had been rejected by it before multiple times. The day started with good volumes and strong candles. However, it once again got rejected by same resistance zone
Price was below HTF resistance and had been rejected by it before multiple times. The day started with good volumes and strong candles. However, it once again got rejected by same resistance zone
One line thesis for top momentum stocks:
#ADANIGREEN - Largest govt contracts
#LAURUSLABS - Superb Q results, CDMO, Sector Tailwinds
#ALKYLAMINE - Duopoly, Proxy to Pharma(60%) and agroChem(40%) boom
#GMMPFAUDLR - Market leader, MNC, Pharma Proxy
(1/n)
#ADANIGREEN - Largest govt contracts
#LAURUSLABS - Superb Q results, CDMO, Sector Tailwinds
#ALKYLAMINE - Duopoly, Proxy to Pharma(60%) and agroChem(40%) boom
#GMMPFAUDLR - Market leader, MNC, Pharma Proxy
(1/n)
#GRANULES - Pharma boom, API, Cos Moving from China to India for APIs.
#DCAL - CDMO business
#BSOFT - Big wins from the likes of Microsoft, Oracle, etc
#DIXON - Marquee clients like Samsung, Philips, Xiaomi, Proxy to electronics consumption theme in India
(2/n)
#DCAL - CDMO business
#BSOFT - Big wins from the likes of Microsoft, Oracle, etc
#DIXON - Marquee clients like Samsung, Philips, Xiaomi, Proxy to electronics consumption theme in India
(2/n)
#TATACOMM - New investments from FIIs, WFH, Few players left, INet growth
#DHANUKA - Agrochem boom, Asset light business, collaboration with innovators
#AFFLE - Digital consumption growth
#INTELLECT - Financial platform, new product financial services-ready public cloud
(3/n)
#DHANUKA - Agrochem boom, Asset light business, collaboration with innovators
#AFFLE - Digital consumption growth
#INTELLECT - Financial platform, new product financial services-ready public cloud
(3/n)
Stocks for 18/08/20 Intraday
#SUNPHARMA
#CONCOR
#TATACONSUM
#TITAN
#TCS
#UPL
#GRANULES
#DIVISLAB
#IOLCP
#DRREDDY
Based on NR7, Volume and Volatility concepts
#SUNPHARMA
#CONCOR
#TATACONSUM
#TITAN
#TCS
#UPL
#GRANULES
#DIVISLAB
#IOLCP
#DRREDDY
Based on NR7, Volume and Volatility concepts
Results of the Day : Very Good Day for me.
4/10 Stocks gave tradeable moves.
1/4 : #TITAN
Price broke previous session's resistance with Volume and Good VWAP Structure. Got out of the trade since momentum was getting weak.
+3.7R profits booked
4/10 Stocks gave tradeable moves.
1/4 : #TITAN
Price broke previous session's resistance with Volume and Good VWAP Structure. Got out of the trade since momentum was getting weak.
+3.7R profits booked
Hello Traders, Below is our trade plan for upcoming week. It will be a buy & hold portfolio with time frame of 30 trading sessions #NIFTY #BANKNIFTY #fmcg #INFY #TCS #GranulesIndia #Bayercorp #SBIcard #Cipla #tataconsumer #Alltimehigh #Dhoni #DhoniRetires #ThalaDhoni #CSK
Below is the link to chart where we have tried explaining the idea behind buy on Granules #Granules #API #momentuminvesting #alltimehigh #ATH
tradingview.com/chart/GRANULES…
tradingview.com/chart/GRANULES…
Below is the link to chart where we have tried explaining the idea behind buy on Tata Consumer #TataConsumer #fmcg #Nifty #banknifty
tradingview.com/chart/TATACONS…
tradingview.com/chart/TATACONS…
Stocks for 13/08/20 Intraday
#ICICIBANK
#BANDHANBNK
#HDFCBANK
#KOTAKBANK
#TATASTEEL
#TATACONSUM
#LnT
#GRANULES
#ESCORTS
#UJJIVAN
#McDOWELL_N
#PEL
Based on NR7, Volume and Volatility concepts
#ICICIBANK
#BANDHANBNK
#HDFCBANK
#KOTAKBANK
#TATASTEEL
#TATACONSUM
#LnT
#GRANULES
#ESCORTS
#UJJIVAN
#McDOWELL_N
#PEL
Based on NR7, Volume and Volatility concepts
Results of the Day : 2/12 stocks gave tradeable moves
1/2 : #LnT
After a bearish, wick forming start, price hovered around but gave Bullish breakout at 1:10 pm. Trade was taken after Bullish confirmation.
+2R profits booked
1/2 : #LnT
After a bearish, wick forming start, price hovered around but gave Bullish breakout at 1:10 pm. Trade was taken after Bullish confirmation.
+2R profits booked
2/2 : #TATACONSUM
Again, after a bearish start, price broke All Time High at 9:25. A little supply came in at 9:30 but trade was taken after Bullish confirmation at 9:35.
+2R profits booked, details on chart.
Please Like / Retweet !
Again, after a bearish start, price broke All Time High at 9:25. A little supply came in at 9:30 but trade was taken after Bullish confirmation at 9:35.
+2R profits booked, details on chart.
Please Like / Retweet !
Burnol?
Really complex APIs, formulations, branded segments, home diagnostics and whatnot. If growth in API happens, should cross all-time high. The stock corrected 30% even after the best Nos. Debt-free. repaid the debt of 100 Cr in last 5 yrs
expresspharma.in/latest-updates…
Really complex APIs, formulations, branded segments, home diagnostics and whatnot. If growth in API happens, should cross all-time high. The stock corrected 30% even after the best Nos. Debt-free. repaid the debt of 100 Cr in last 5 yrs
expresspharma.in/latest-updates…
Invested by looking at the complexity of API they make, believe me, I am a chemist.
Few silent features: 80% US market share in Loratidine API that's amazing. Other APIs doing well are Montelukast, Atorvastatin, Rosuvastatin, all complex.
Few silent features: 80% US market share in Loratidine API that's amazing. Other APIs doing well are Montelukast, Atorvastatin, Rosuvastatin, all complex.
3 Diabetic APIs under development. API Sales Revenue during the year 2020-21 grew by 14.74 percent at Rs. 473.95 crores with an impressive growth of 28 percent in Domestic and 10 percent in Exports.
